Common Stock Compensation

9 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

(10) Common Stock Compensation

Stock Option Activity Summary

The Company’s stock option activity for the nine months ended March 31, 2020, is as follows:

	Shares (in thousands)			Weighted Average Exercise Price
Outstanding at June 30, 2019		324		$	5.71
Granted		10			1.85
Exercised		—			—
Canceled or expired		(8	)		4.07
Outstanding at March 31, 2020		326		$	5.68

The aggregate intrinsic value of options exercisable at March 31, 2020 was $0, as the fair value of the Company’s common stock is less than the exercise prices of these options. The remaining stock-based compensation expense of $33 thousand related to stock options will be recognized over a weighted-average period of 0.57 years.

The table below details the Company’s stock options outstanding as of March 31, 2020:

Range of exercise prices	Number Outstanding		Options Outstanding Weighted- Average Remaining Contractual Life (years)		Weighted- Average Exercise Price		Number Exercisable		Options Exercisable Weighted- Average Exercise Price
$1.85 – 3.55		76,500		3.03	$	3.43		66,500	$	3.43
$5.30 – 5.85		119,653		7.11		5.48		76,909		5.49
$6.00 – 8.35		130,000		4.65		7.19		86,000		6.59
$1.85 – 8.35		326,153		5.17	$	5.68		229,409	$	5.31

Compensation costs recognized related to stock option awards were $43 thousand for each of the three months ended March 31, 2020 and 2019, and $128 thousand for each of the nine months ended March 31, 2020 and 2019.

Restricted Stock

The Company’s restricted stock activity for the nine months ended March 31, 2020, is as follows:

	Shares (in thousands)			Weighted Average Grant-Date Fair Value
Outstanding at June 30, 2019		208		$	4.06
Granted		5			2.47
Vested		(63	)		3.77
Canceled or expired		(11	)		3.97
Outstanding at March 31, 2020		139		$	3.96

Stock compensation expenses related to restricted stock were $52 thousand and $64 thousand for the three months ended March 31, 2020 and 2019, respectively, and $154 thousand and $77 thousand for the nine months ended March 31, 2020, and 2019, respectively. The remaining stock-based compensation expense of $359 thousand related to restricted stock awards granted will be recognized over a weighted-average period of 1.74 years.